Anlotinib or platinum-pemetrexed as second-line therapy in EGFR T790M-negative lung cancer

Clinical management of T790M-negative patients after first-line epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) treatment failure is controversial. Anlotinib is a novel multi-target TKI for tumor angiogenesis and tumor cell proliferation, and it has been approved as a thirdli...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of palliative medicine 2020-07, Vol.9 (4), p.1681-1687
Hauptverfasser:	Zhong, Run-Bo, Xu, Jian-Lin, Lou, Yu-Qing, Chu, Tian-Qing, Zhong, Hua, Han, Bao-Hui
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics ErbB Receptors - genetics Humans Indoles Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation Pemetrexed - therapeutic use Platinum - therapeutic use Protein Kinase Inhibitors - therapeutic use Quinolines Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!